KRAS and adenocarcinoma: Furthermore, concurrent mutations of tumor suppressor genes in KRAS-mutant adenocarcinoma patients (e.g. TP53, LKB1 or KEAP1) should be taken into account because such mutational pattern is related to the control of distinct tumorigenic pathways [53–57].